Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · IEX Real-Time Price · USD
16.59
+1.19 (7.73%)
At close: May 17, 2024, 4:00 PM
16.84
+0.25 (1.51%)
After-hours: May 17, 2024, 6:10 PM EDT
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $80.89M in the twelve months ending February 29, 2024, with 94.02% growth year-over-year. Revenue in the quarter ending February 29, 2024 was $16.59M with 30.74% year-over-year growth. In the fiscal year ending November 30, 2023, Nurix Therapeutics had annual revenue of $76.99M with 99.31% growth.
Revenue (ttm)
$80.89M
Revenue Growth
+94.02%
P/S Ratio
12.16
Revenue / Employee
$284,813
Employees
284
Market Cap
983.19M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
Nov 30, 2019 | 31.12M | - | - |
Nov 30, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Ironwood Pharmaceuticals | 413.55M |
Artivion | 368.21M |
Innoviva | 311.59M |
BioLife Solutions | 137.30M |
Standard BioTools | 126.76M |
Simulations Plus | 64.67M |
Ocular Therapeutix | 59.84M |
Liquidia | 15.97M |
NRIX News
- 4 days ago - Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024) - GlobeNewsWire
- 11 days ago - Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 - GlobeNewsWire